Education
About Us
Working with TipRanks
Follow Us
ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
ABVC Stock Chart & Stats
$2.10
-$0.06(-10.00%)
At close: 4:00 PM EST
$2.10
-$0.06(-10.00%)
Day’s Range― - ―
52-Week Range$0.61 - $5.48
Previous CloseN/A
Volume151.09K
Average Volume (3M)95.05K
Market Cap
$36.89M
Enterprise Value$23.80M
Total Cash (Recent Filing)$745.83K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding25,423,655
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)4.46
Price to Sales (P/S)62.24
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue14.95
Enterprise Value/Gross Profit14.95
Enterprise Value/Ebitda-3.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetMaterial deleveraging and higher assets reduce near-term financing pressure and improve negotiating leverage with lenders or partners. A stronger balance sheet gives durable runway for clinical development, lowering immediate dilution risk and enabling strategic choices over the next several quarters.
Very High Gross MarginsNear‑100% gross margins imply product or candidate economics that can scale favorably once commercialized. That structural margin advantage supports long‑term operating leverage potential, meaning revenue growth could translate to rapid margin expansion if R&D and SG&A are controlled.
Proprietary Clinical-stage PipelineOwning novel, proprietary drug candidates creates durable strategic optionality: licensing, partnerships, or milestone-driven financing. Successful trial outcomes would materially change cash flow prospects and competitive position, making the asset base a long-term fundamental strength.
Bears Say
Weak Cash GenerationThe company has not demonstrated consistent internal cash generation and reported zero operating/free cash flow in 2025 after multi-year outflows. This creates structural reliance on external financing, increasing dilution risk and constraining the ability to fund trials or scale operations sustainably.
Deep Ongoing LossesPersistent, large net losses relative to revenues and a very negative net margin signal that operating economics are currently unsustainable. Continued losses erode equity returns and heighten the need for capital; absent clear pathway to profitability, long‑term viability depends on external funding and trial success.
Tiny, Volatile Revenue BaseA very small and inconsistent revenue stream limits the company's ability to absorb fixed R&D and G&A costs and to demonstrate commercial traction. This structural revenue volatility makes forecasting cash needs difficult and raises execution risk over the next several quarters.
ABVC BioPharma News
ABVC FAQ
What was ABVC BioPharma, Inc.’s price range in the past 12 months?
ABVC BioPharma, Inc. lowest stock price was $0.61 and its highest was $5.48 in the past 12 months.
What is ABVC BioPharma, Inc.’s market cap?
ABVC BioPharma, Inc.’s market cap is $36.89M.
When is ABVC BioPharma, Inc.’s upcoming earnings report date?
ABVC BioPharma, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 22 days.
How were ABVC BioPharma, Inc.’s earnings last quarter?
ABVC BioPharma, Inc. released its earnings results on Nov 17, 2025. The company reported -$0.088 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.088.
Is ABVC BioPharma, Inc. overvalued?
According to Wall Street analysts ABVC BioPharma, Inc.’s price is currently Overvalued.
Does ABVC BioPharma, Inc. pay dividends?
ABVC BioPharma, Inc. does not currently pay dividends.
What is ABVC BioPharma, Inc.’s EPS estimate?
ABVC BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABVC BioPharma, Inc. have?
ABVC BioPharma, Inc. has 25,423,655 shares outstanding.
What happened to ABVC BioPharma, Inc.’s price movement after its last earnings report?
ABVC BioPharma, Inc. reported an EPS of -$0.088 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.685%.
Which hedge fund is a major shareholder of ABVC BioPharma, Inc.?
Currently, no hedge funds are holding shares in ABVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ABVC BioPharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
447.44%
12-Months-Change
Fundamentals
Return on Equity
-40.32%
Trailing 12-Months
Asset Growth
10.98%
Trailing 12-Months
Company Description
ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Technical Analysis
CervoMed
―
MindWalk Holdings
―
Jasper Therapeutics
―
MiNK Therapeutics
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
―
Insiders
1.32% Mutual Funds
0.05% Other Institutional Investors
97.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---